96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

7 trials found

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-011621-14-DE (EUCTR)	12/05/2010	26/01/2010	A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ...	A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ...	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ...	Product Name: AIN457 Product Code: AIN457	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		Germany;Austria
2	EUCTR2009-011621-14-AT (EUCTR)	12/11/2009	19/10/2009	A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ...	A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ...	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ...	Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: No ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		Germany;Austria
3	NCT01009281 (ClinicalTrials.gov)	October 2009	5/11/2009	An Open Label Safety and Tolerability Study of AIN457in Patients With Moderate to Severe Crohn's Dis ...	A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457(Anti IL-17 Mo ...	Crohn's Disease;Inflammatory Bowel Disease	Drug: AIN457	Novartis Pharmaceuticals	NULL	Terminated	18 Years	75 Years	All	7	Phase 2	United States;Austria;Canada;Germany;Poland
4	EUCTR2008-008359-40-DE (EUCTR)	08/09/2009	23/06/2009	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study t ...	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study t ...	Moderate to severe Crohn's disease (CDAI >/= 220 and MedDRA version: 9.1;Level: LLT;Classification c ...	Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: not available Other descriptive name: rh ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		Germany;Poland;Austria
5	EUCTR2008-008359-40-PL (EUCTR)	02/09/2009	07/04/2009	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ...	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ...	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ...	Product Name: AIN457 Product Code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) rhum ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		Germany;Austria;Poland
6	EUCTR2008-008359-40-AT (EUCTR)	07/05/2009	31/03/2009	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ...	A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ...	Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ...	Product Name: AIN457 Product Code: AIN457	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		Germany;Poland;Austria
7	NCT00584740 (ClinicalTrials.gov)	August 2008	21/12/2007	Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study t ...	Crohn's Disease	Drug: AIN457;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	75 Years	All	59	Phase 2	Germany;Canada;United States

First Previous1Next Last